Русский
Nasopharyngeal cancer. ESMO 2024 news
DOI: https://dx.doi.org/10.18565/pharmateca.2024.7.50-55
P.V. Golubev, L.V. Bolotina, E.S. Kuzmina, I.A. Pokataev, A.V. Golubeva, E.P. Kyanzhin, V.M. Kuzmin, V.N. Galkin
1) Moscow City Hospital n.a. S.S. Yudin of the Moscow Healthcare Department, Moscow, Russia; 2) P. Hertsen Moscow Oncological Research Institute, Branch of the National Medical Research Center of Radiology, Moscow, Russia; 3) Samara State Medical University, Samara, Russia; 4) I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Nasopharyngeal cancer (NPC) belongs to the group of orphan malignant neoplasms. This nosology is characterized by a modest arsenal of treatment options for both localized and widespread forms. The above facts explain the extremely unsatisfactory results of treatment of patients with nasopharyngeal carcinoma. Major recent international conferences have not presented breakthrough studies in this area beyond the Chinese protocols using chemo-immunotherapy for recurrent/metastatic forms of the disease. The exception was the latest congress of the European Society of Medical Oncology (ESMO), which was held from September 13 to 17 in Barcelona, Spain. In this review article, we discuss the most significant studies on the treatment of patients with nasopharyngeal carcinoma that were reported at ESMO 2024 and may change the routine practice of an oncologist in the near future.
About the Autors
Corresponding author: Pavel V. Golubev, Cand. Sci. (Med.), Oncologist, Chemotherapy Department No. 2 of the Oncology Center No. 1, Moscow City Hospital n.a. S.S. Yudin of the Moscow Healthcare Department, Russia; golubev194@gmail.com
Similar Articles
